Xenbase Image ID: 144363

Figure S3. Inhibiting Xfz5 Expression Causes Reduced Eye Size and Delayed Retinal Development The eye size on the Xfz5 MO-injected side (A and I) is smaller than on the uninjected control side (E and M), although lamination of the neural retina is normal as demonstrated by Hoechst nuclear staining. Ganglion and amacrine cells (B and F; α-Pax6 antibody staining) as well as rod photoreceptors (J and N; α-rhodopsin antibody staining) are properly positioned within their respective layers on both the uninjected (F and N, respectively) and the injected side (B and J, respectively). eGFP expression (C and K) identifies the Xfz5 MO-injected side. (D), (H), (L), and (P) are the merged images of Hoescht nuclear staining, antibody staining, and eGFP expression. Note that the antibody staining on the uninjected side extends more peripherally than that on the injected side (compare brackets in [L] and [P]), suggesting that the retina on the injected side has a larger CMZ reminiscent of a more immature retina. (Q–T) BrDU analysis on stage 41 retinas. (Q and R) BrDU labeling is restricted to the CMZ on the uninjected control side. (S and T) BrDU- labeled cells are detected in the central retina as well as the CMZ on the Xfz5 MO injected side, indicating that the central retina is not fully postmitotic and may be delayed in its development. The number of BrDU cells within the CMZ is similar for control versus the Xfz5 MO-injected side. Image published in: Van Raay TJ et al. (2005) Copyright © 2005. This image is reproduced with permission of the publisher and the copyright holder. This is an Open Access article distributed under the terms of the Creative Commons Attribution License. Larger Image Printer Friendly View

Return to previous page